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Abstract
Background: The tachykinins, substance P and neurokinin A, present in sensory nerves and
inflammatory cells such as macrophages and dendritic cells, are considered as pro-inflammatory
agents. Inflammation of the airways and lung parenchyma plays a major role in the pathogenesis of
chronic obstructive pulmonary disease (COPD) and increased tachykinin levels are recovered from
the airways of COPD patients. The aim of our study was to clarify the involvement of the tachykinin
NK1 receptor, the preferential receptor for substance P, in cigarette smoke (CS)-induced
pulmonary inflammation and emphysema in a mouse model of COPD.
Methods: Tachykinin NK1 receptor knockout (NK1-R-/-) mice and their wild type controls (all in
a mixed 129/sv-C57BL/6 background) were subjected to sub acute (4 weeks) or chronic (24 weeks)
exposure to air or CS. 24 hours after the last exposure, pulmonary inflammation and development
of emphysema were evaluated.
Results: Sub acute and chronic exposure to CS resulted in a substantial accumulation of
inflammatory cells in the airways of both WT and NK1-R-/- mice. However, the CS-induced increase
in macrophages and dendritic cells was significantly impaired in NK1-R-/- mice, compared to WT
controls, and correlated with an attenuated release of MIP-3α/CCL20 and TGF-β1. Chronic
exposure to CS resulted in development of pulmonary emphysema in WT mice. NK1-R-/- mice
showed already enlarged airspaces upon air-exposure. Upon CS-exposure, the NK1-R-/- mice did
not develop additional destruction of the lung parenchyma. Moreover, an impaired production of
MMP-12 by alveolar macrophages upon CS-exposure was observed in these KO mice. In a
pharmacological validation experiment using the NK1 receptor antagonist RP 67580, we confirmed
the protective effect of absence of the NK1 receptor on CS-induced pulmonary inflammation.
Conclusion: These data suggest that the tachykinin NK1 receptor is involved in the accumulation
of macrophages and dendritic cells in the airways upon CS-exposure and in the development of
smoking-induced emphysema. As both inflammation of the airways and parenchymal destruction
are important characteristics of COPD, these findings may have implications in the future
treatment of this devastating disease.
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Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death worldwide and a major bur-
den on healthcare systems. Moreover, its prevalence and
mortality are expected to escalate in the coming decades
[1]. COPD is a chronic respiratory disease that is charac-
terized by an abnormal inflammatory response of the
lungs to noxious particles and gases. This leads to obstruc-
tion of the small airways and destruction of the lung
parenchyma (emphysema), resulting in a slowly progres-
sive development of airflow limitation that is not fully
reversible [2,3].
Cigarette smoke is the major risk factor for the develop-
ment of COPD, and it has been shown that smoking leads
to airway inflammation with an increase of inflammatory
cells of both the innate and adaptive immune system.
Indeed, an exaggerated accumulation of macrophages
[4,5], neutrophils [6,7], dendritic cells [8,9] and CD8+ T-
lymphocytes [10] has been observed in lungs of COPD
patients. Moreover, in patients with severe COPD, lym-
phoid follicles containing T- and B-lymphocytes are
present in the bronchial wall [11].
The tachykinins, substance P and neurokinin A, are
present in sensory afferent nerves and inflammatory cells
in the airways. They may be released by a variety of stimuli
(e.g. cigarette smoke, ozone) and have various effects
including smooth muscle contraction, facilitation of
cholinergic neurotransmission, submucosal gland secre-
tion, vasodilatation, increase in vascular permeability,
stimulation of mast cells, B and T lymphocytes and mac-
rophages, chemoattraction of eosinophils and neu-
trophils and the vascular adhesion of neutrophils [12].
Tachykinins mediate their effects by stimulation of tachy-
kinin NK1, NK2 and NK3 receptors [13]. NK1 receptors are
mainly involved in neurogenic inflammation (microvas-
cular leakage and mucus secretion) while NK2 receptors
are considered to be important in smooth muscle contrac-
tion. NK3 receptors have also been detected in the airways,
and may have an important role in localized neural regu-
lation of airflow to the lungs [14].
Several lines of evidence indicate a role for tachykinins in
chronic obstructive pulmonary disease (COPD). Elevated
levels of tachykinins have been recovered from the air-
ways of patients with COPD [15]. Cigarette smoke, the
main causative agent of COPD activates C-fiber endings,
causing the release of tachykinins [16,17] and lowers the
threshold for activation of these nerve endings [18]. More-
over, human alveolar macrophages possess functional
NK1 receptors on their surface, which are upregulated in
smokers [19]. In guinea pigs, chronic exposure to cigarette
smoke increases the synthesis of substance P in jugular
ganglia innervating the lung and airways [20]. Activation
of C-fibers and the subsequent release of tachykinins
induces neurogenic inflammation in the airways [21].
Furthermore, cigarette smoke-induced airway neu-
trophilia was attenuated by a dual tachykinin NK1/NK2
receptor antagonist in guinea pigs [22].
The purpose of this study was to characterize the precise
role of the tachykinin NK1 receptor in a mouse model of
cigarette smoke-induced COPD [23,24], more particularly
in pulmonary inflammation, lymphoid follicle formation
and development of pulmonary emphysema.
Methods
Animals
Tachykinin NK1 receptor knockout (NK1-R-/-) and wild
type (WT) mice were derived as described from the mating
of heterozygous tachykinin NK1 receptor mice [25]. The
targeting construct was derived from a mouse 129/sv
strain genomic library and targeted clones were injected
into C57BL/6 blastocysts. Chimaeric males were mated
with C57BL/6 females. The mice were bred from succes-
sive generations of sibling NK1-R-/- and WT mice and can
be thought of as representing a recombinant inbred strain.
The NK1-R-/- and WT breeding pairs were provided by the
lab of S. Hunt (Cambridge, UK). The animals were bred
locally and maintained in a conventional animal house in
the animal research facilities of the Faculty of Medicine
and Health Sciences, Ghent University Hospital and
received food and water ad libitum. The NK1-R-/- and WT
mice were in good health and were fertile. No remarkable
differences were observed between both genotypes. Male
C57BL/6 mice were purchased from Harlan (Zeist, the
Netherlands). The local Ethics Committee for animal
experimentation of the faculty of Medicine and Health
Sciences (Ghent, Belgium) approved all in vivo manipula-
tions.
NK1 receptor antagonist treatment
In a pharmacological validation experiment of sub acute
CS-exposure C57BL/6 mice were treated daily – 30 min-
utes before air- or CS-exposure – with the NK1 receptor
antagonist RP 67580 ((3aR,7aR)-Octahydro-2- [1-imino-
2-(2-methoxyphenyl)ethyl]-7, 7-diphenyl-4H-isoindol)
(Tocris, Bristol, UK) for 2 weeks. The antagonist was dis-
solved in 200 μl diluent (PBS with 20% DMSO) at a con-
centration of 0.1 μg/μl or 1 μg/μl and administered
intraperitoneally. Control groups received IP injections of
200 μl diluent (PBS with 20% DMSO).
Smoke exposure
Mice (male, 8–12 weeks, N = 8 per experimental group)
were exposed whole body to the tobacco smoke of 5 ciga-
rettes (Reference Cigarette 1R3, University of Kentucky,
Lexington, KY) three times a day with 2 hours smoke-freePage 2 of 12
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weeks (chronic exposure). An optimal smoke:air ratio of
1:12 was obtained. For the experiment with the NK1 recep-
tor antagonist (RP 67580) mice (male, 8 weeks, N = 8 per
experimental group) where exposed whole body to the
tobacco smoke of 5 cigarettes (Reference Cigarette 3R4F
without filter, University of Kentucky, Lexington, KY) four
times a day with 30 minutes smoke-free intervals, 5 days
a week for 2 weeks. An optimal smoke:air ratio of 1:6 was
obtained. Smoke was generated with a standard smoking
apparatus with the chamber adapted for groups of mice
(chamber dimensions: 24 × 14 × 14 cm = 4700 cm3). The
control groups were exposed to air. Carboxyhemoglobin
in serum of smoke-exposed mice reached a non-toxic level
of 8.3 ± 1.4% (compared to 1.0 ± 0.2% in air-exposed
mice (n = 7 for both groups)), which is similar to carbox-
yhemoglobin blood concentrations of human smokers.
Bronchoalveolar lavage
24 hours after the last smoke exposure, mice were killed
with an overdose of pentobarbital (Sanofi, Libourne,
France) and a tracheal cannula was inserted. 1 ml of
Hank's balanced salt solution (HBSS), free of ionised cal-
cium and magnesium but supplemented with 0.05 mM
sodium EDTA was instilled 4 times via the tracheal can-
nula and recovered by gentle manual aspiration. The
recovered bronchoalveolar lavage fluid (BALF) was centri-
fuged (1800 rpm for 10 min at 4°C). The supernatant was
discarded and the cell pellet was washed twice and finally
resuspended in 1 ml of HBSS. A total cell count was per-
formed in a Bürker chamber and the differential cell
counts on at least 400 cells were performed on cytocentri-
fuged preparations (Cytospin 2; Shandon Ltd., Runcorn,
UK) using standard morphologic criteria after staining
with May-Grünwald-Giemsa. Flow cytometric analysis of
BAL-cells was also performed to enumerate dendritic cells.
Lung digests
Immediately after bronchoalveolar lavage, the lung and
systemic circulation was rinsed with saline supplemented
with 5 mM EDTA. The left lung was used for histology, the
right lung for the preparation of a cell suspension as
detailed previously [23,24,26]. Briefly, the lung was thor-
oughly minced, digested, subjected to red blood cell lysis,
passed through a 50 μm cell strainer, and kept on ice until
labeling. Cell counting was performed with a Z2 Beck-
man-Coulter particle counter (Beckman-Coulter, Ghent,
Belgium).
Labeling of BAL-cells and lung single-cell suspensions for 
flow cytometry
Cells were pre-incubated with Fc-receptor blocking anti-
body (anti CD16/CD32, clone 2.4G2) to reduce non-spe-
cific binding. Monoclonal antibodies used to identify
mouse dendritic cell (DC) populations were: biotinylated
anti-CD11c (N418 hybridoma, gift from M. Moser, Brus-
sels Free University, Belgium) and phycoerythrin (PE)-
conjugated anti-IAb (AF6-120.1), followed by streptavi-
dine-allophycocyanine (Sav-APC). We discriminated
between macrophages and DCs using the methodology
described by Vermaelen et al. [27]. After gating on the
CD11c-bright population, two peaks of autofluorescence
can be distinguished. Macrophages are identified as the
CD11c-bright, high autofluorescent population, and do
not express MHCII. DCs are identified as CD11c-bright,
low autofluorescent cells, which strongly express MHCII.
DCs enumerated by these criteria correspond with mye-
loid DCs. Mouse T-cell populations were characterized
with the following monoclonal antibodies: fluorescein
isothiocyanate (FITC)-conjugated anti-CD4 (L3T4), FITC-
conjugated anti-CD8 (Ly-2) and biotinylated anti-CD3
(145-2C11). PE-conjugated anti-CD69 (H1.2F3) was
used to evaluate the activation status of the T-cells. Bioti-
nylated anti-CD3 was revealed by incubation with Sav-
APC. All antibodies were obtained from Pharmingen
(Beckton Dickinson, Erembodegem, Belgium). Finally,
cell suspensions were incubated with 7-amino-actinomy-
cin (7-AAD) to exclude dead cells (7-AAD positive cells).
All labelling reactions were performed on ice with FACS-
buffer. Flow cytometric data acquisition was performed
on a dual-laser FACS Vantage™ flow cytometer running
CELLQuest™ software (Beckton Dickinson, Erembod-
egem, Belgium). FlowJo software (Tree Star Inc. Ashland,
OR) was used for data analysis.
Histology
The left lung was fixated by intratracheal infusion of fixa-
tive (4% paraformaldehyde), as previously described
[23,24,26]. After excision, the lung was immersed in fresh
fixative during 2 h. The lung lobe was embedded in paraf-
fin and cut in 3 μm transversal sections. Lung tissue sam-
ples were stained with hematoxylin and eosin, and
examined by light microscopy for histological sections.
For each animal, 10 fields at a magnification of 200× were
captured randomly from the 4 different zones of the left
lung (upper, middle upper, middle basal and basal zone)
using a Zeiss KS400 image analyzer platform (KS400,
Zeiss, Oberkochen, Germany).
Quantification of emphysema
Emphysema is a structural disorder characterized by dam-
age to the lung parenchyma. The destruction of the alveo-
lar walls will lead to enlargement of the alveolar airspaces.
The alveolar airspace enlargement was determined by
mean linear intercept (Lm) as described previously
[23,28], using image analysis software (Image J 1.33).
Only sections without cutting artefacts, compression or
hilar structures (airway or blood vessel with a diameter
larger than 50 μm) were used in the analysis. The Lm was
measured by placing a 100 × 100 μm grid over each field.Page 3 of 12
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number of alveolar intercepts gives the average distance
between alveolated surfaces, or the Lm. The Lm was meas-
ured by 2 independent observers, with a positive correla-
tion (p < 0.01).
The destruction of alveolar walls was quantified by the DI
[29]. A grid with 42 points that were at the center of hair-
line crosses was superimposed on the lung field. Struc-
tures lying under these points were classified as normal
(N) or destroyed (D) alveolar and/or duct spaces. Points
falling over other structures, such as duct walls, alveolar
walls, etc. did not enter into the calculations. The DI was
calculated from the formula: DI = D/(D + N) × 100.
Morphometric quantification of lymphoid follicles
To evaluate the presence of lymphoid follicles in lung tis-
sue after 24 weeks of smoke exposure, lung sections
obtained from formalin-fixed, paraffin-embedded lung
lobes were subjected to the following immunohistologi-
cal CD3/B220 double staining [26,30]: at first, sections
were incubated with Boehringer blocking reagent with tri-
ton and primary antibody anti-CD3, followed by goat-
anti-rabbit biotin (both obtained from DakoCytoma-
tion). Then, slides were incubated with streptavidin horse-
radish peroxidase and colored with DAB. In a second step,
sections were stained with anti-B220-biotin after Boe-
hringer blocking (with triton). Finally, slides were incu-
bated with streptavidin alkaline phosphatase
(DakoCytomation) and colored with Vector blue (Vector
Laboratories, Inc., Burlingame, California, USA). Lym-
phoid follicles were defined as accumulations of at least
50 cells and counted in the tissue area surrounding the air-
ways (airway perimeter < 2000 μm). Results were
expressed as counts relative to the numbers of airways per
lung section.
Immunohistochemistry for MMP-12
Sections obtained from formalin-fixed, paraffin-embed-
ded lung lobes were subjected to the following immuno-
histological staining sequences [24]: blocking reagent,
goat-anti-mouse MMP-12 (Santa Cruz Biotechnology,
Santa Cruz, USA) or goat IgG isotype control and detec-
tion with Vectastain Elite Goat IgG ABC Kit (Vector, Burl-
ingame, USA) and DAB substrate (DAKO, Glostrup,
Denmark). Sections were counterstained with haematox-
ylin. The MMP-12 staining was simultaneously evaluated
by two observers unaware of the treatment of the animals.
The intensity of the MMP-12 staining was scored on a four
point scale 0) none or very weak staining; 1) weak stain-
ing; 2) moderate staining; 3) intense staining.
Measurement of chemokines
Using commercially available ELISA kits (R&D Systems),
MIP-3α (Macrophage Inflammatory Protein-3α), KC
(mouse IL-8) and activated TGF-β1 protein levels were
determined in BAL fluid after 24 weeks of CS-exposure.
Statistical analysis
All results are reported as mean ± standard error of the
mean (SEM). Statistical analysis was performed with
Sigma Stat software (SPSS 11.0 Inc, Chicago, IL, USA)
using non-parametric tests (Kruskall-Wallis, Mann-Whit-
ney U). P-values < 0.05 were considered as significant.
Results
CS-induced increase of inflammatory cells in BAL fluid and 
lung tissue
Both sub acute and chronic CS-exposure induced an
enhanced accumulation of inflammatory cells in the
bronchoalveolar lavage fluid, compared to air-exposed
controls (Figure 1). Increased numbers of macrophages,
DCs, neutrophils and lymphocytes were recovered by
bronchoalveolar lavage in both CS-exposed tachykinin
NK1 receptor WT and NK1-R-/- mice (Figure 1). However,
the CS-induced increase in total cells, macrophages and
DCs was significantly attenuated in the NK1-R-/- mice at
both the sub acute and chronic time-point (Figure 1A–C).
In contrast, no differences in the accumulation of neu-
trophils and lymphocytes were observed between smoke-
exposed WT and NK1-R-/- animals (Figure 1D–E). At the
sub acute time-point, air-exposed NK1-R-/- mice had sig-
nificantly less DCs in their airways than WT control ani-
mals. This difference disappeared however with ageing in
the chronic exposed group (Figure 1C).
In lung digests, sub acute and chronic CS-exposure
induced increases in DCs and activated (CD69+) CD4+
and CD8+ T-lymphocytes. No differences were observed
between WT and NK1-R-/- animals (data not shown).
Chronic CS-induced increase of peribronchial lymphoid 
follicles
Immunohistochemistry using anti-CD3 and anti-B220
monoclonal antibodies, staining T- and B-lymphocytes
respectively, revealed the presence of only a few small
lymphoid follicles in lung tissue surrounding the airways
of air-exposed WT and NK1-R-/- mice (Figure 2). Chronic
CS-exposure significantly increased the number of these
peribronchal lymphoid follicles (Figure 2). There were no
differences in follicle numbers between WT and NK1-R-/-
mice (Figure 2).
Chronic CS-induced increase of inflammatory mediators in 
BAL fluid
To gain more insight into the mechanisms of airway
inflammation in WT and NK1-R-/- mice, we measured pro-
tein levels of MIP-3α/CCL20, KC (mouse homolog for IL-
8) and activated TGF-β1 in BAL fluid supernatant.Page 4 of 12
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Effect of cigarette smoke exposure on cell differentiation in bronchoalveolar lavage fluidFigure 1
Effect of cigarette smoke exposure on cell differentiation in bronchoalveolar lavage fluid. Total bronchoalveolar 
lavage (BAL) cells and cell differentiation in BAL fluid of wild type and NK1-R-/- mice upon sub acute (4 weeks) and chronic (24 
weeks) exposure to air or cigarette smoke: (A) Total BAL cells, (B) macrophages, (C) dendritic cells, (D) neutrophils and (E) 
lymphocytes. Results are expressed as means ± SEM. N = 8 animals per group (* p < 0.05).
Respiratory Research 2009, 10:37 http://respiratory-research.com/content/10/1/37Chronic CS-exposure significantly increased the levels of
MIP-3α/CCL20 in both WT and NK1-R-/- mice, compared
to air-exposed controls. The increase in MIP-3α/CCL20
CS-exposed NK1-R-/- mice was attenuated, compared to
the CS-exposed WT mice, but this difference did not reach
statistical significance (p = 0.066) (Figure 3A). Upon
chronic CS-exposure, the protein levels of KC were equally
increased in both WT and NK1-R-/- mice (Figure 3B).
Quantification of pulmonary lymphoid follicles upon chronic cigarette smoke exposureFigure 2
Quantification of pulmonary lymphoid follicles upon 
chronic cigarette smoke exposure. Peribronchial lym-
phoid follicles in lung tissue of wild type and NK1-R-/- mice 
upon chronic (24 weeks) exposure to air or cigarette smoke 
(CS) (A). Results are expressed as means ± SEM. N = 8 ani-
mals per group (* p < 0.05). Photomicrographs of peribron-
chial lymphoid follicles in lung tissue of air- and CS-exposed 
wild type and NK1-R-/- mice at 24 weeks (chronic exposure; 
magnification ×200): (B) air-exposed wild type mice, (C) CS-
exposed wild type mice, (D) air-exposed NK1-R-/- mice and 
(E) CS-exposed NK1-R-/- mice. Effect of chronic cigarette smoke exposure on the protein lev ls inflammatory m diat rs in bronchoalveolar lavage fluidFigure 3
Effect of chronic cigarette smoke exposure on the 
protein levels of inflammatory mediators in broncho-
alveolar lavage fluid. Protein levels of inflammatory media-
tors in the bronchoalveolar lavage fluid of wild type and NK1-
R-/- mice upon chronic (24 weeks) exposure to air or ciga-
rette smoke, as measured by ELISA: (A) MIP-3α, (B) KC and 
(C) TGF-β1. Results are expressed as pg/ml (mean ± SEM). 
N = 8 animals per group (* p < 0.05). (MIP-3α: Macrophage 
Inflammatory Protein-3α; KC: mouse interleukin-8; TGF-β1: 
Transforming Growth Factor-β1).Page 6 of 12
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centrations in both genotypes, however the CS-induced
increase in NK1-R-/- mice was significanly impaired, com-
pared to WT mice (Figure 3C).
Chronic CS-induced development of pulmonary 
emphysema
Evaluation of lung morphology demonstrated the pres-
ence of pulmonary emphysema in WT mice upon chronic
CS-exposure, defined by an increased mean linear inter-
cept (Lm) and destructive index (DI), compared to the air-
exposed counterparts (Figure 4). No CS-induced increase
in Lm or DI could be detected in NK1-R-/- mice (Figure 4).
However, baseline values of both Lm and DI were already
higher in air-exposed NK1-R-/- mice, compared to air-
exposed WT mice.
Chronic CS-induced increase of MMP-12 in lung 
macrophages
Because MMP-12 is one of the major proteinases impi-
cated in the development of pulmonary emphysema [31],
we studied the presence of MMP-12 in lung tissue by
immunohistochemistry. Chronic CS-exposure revealed
significantly increased MMP-12 staining in macrophages
of WT mice, compared to air-exposed controls (Figure 5).
Interestingly, the MMP-12 induction upon CS-exposure
was significantly attenuated in NK1-R-/- mice, compared to
WT mice (Figure 5).
Effect of the NK1 receptor antagonist on CS-induced 
inflammation in BAL fluid
Two weeks of CS-exposure significantly increased the
numbers of total BAL cells, macrophages, dendritic cells
and neutrophils in BAL fluid of C57BL/6 mice treated
with diluent (Figure 6A–D). After daily IP injection with
the NK1 receptor antagonist RP 67580, CS-exposure no
longer induced a significant increase in the numbers of
inflammatory cells in the BAL fluid, except for a signifi-
cant increase in neutrophils (Figure 6).
Discussion
In this mouse model of COPD, CS-exposure resulted in an
increase of inflammatory cells in the lavage fluid whereby
a role for the tachykinin NK1 receptor in macrophage and
DCs accumulation was demonstrated. The impaired accu-
mulation of these cell types seems, at least partially, medi-
ated by the attenuated release of the chemokines MIP-3α/
CCL20 and TGF-β1. Absence of the NK1 receptor already
resulted in alveolar destruction in air-exposed mice. This
alveolar enlargement did however not increase further
upon chronic CS-exposure, which correlates with an
impaired production of MMP-12 by alveolar macro-
phages in NK1-R-/- mice. In a pharmacological validation
experiment using a NK1 receptor antagonist (RP67580),
we confirmed the protective effect of absence of the NK1
receptor on sub acute CS-induced pulmonary inflamma-
tion.
Macrophages and DCs are originally derived from mono-
cyte precursors in the bone marrow [32,33]. During
inflammation, increased amounts are recruited into the
airway lumen and the alveoli. This can be mediated by
either increased influx of precursors from the circulation
or increased local proliferation or a combination of both.
In vitro studies revealed a direct chemotactic activity of
substance P through the NK1 receptor. Macrophages and
DCs are known to express the functional tachykinin NK1
receptor [19,34,35] and are chemotactic towards sub-
stance P [36-39]. However, very high concentrations of
agonist are needed for this phenomenon. In vivo, the half
Pulmonary emphysema upon chronic cigarette smoke expo-s reFigure 4
Pulmonary emphysema upon chronic cigarette 
smoke exposure. Mean linear intercept (Lm) (A) and 
destructive index (DI) (B) values of wild type and NK1-R-/- 
mice upon chronic (24 weeks) exposure to air or cigarette 
smoke. Results are expressed as means ± SEM. N = 8 animals 
per group (* p < 0.05).Page 7 of 12
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degraded by neutral endopeptidase. This peptidase is
however inactivated by cigarette smoke [40] which can
lead to increased levels of substance P in smoking animals
and a direct chemotactic activity towards macrophages
and DCs. Nevertheless, an indirect effect may be more
likely as tachykinins can stimulate macrophages, epithe-
lium, endothelium, mast cells and T cells to release medi-
ators responsible for chemotaxis and transmigration of
inflammatory cells through the vessel walls. We found an
increased release of MIP-3α/CCL20 and TGF-β1 into the
BAL fluid after CS-exposure, that was attenuated in the
absence of the tachykinin NK1 receptor. The interaction of
MIP-3α/CCL20 with its receptor CCR6 has been described
as one of the most potent mechanisms for recruitment of
immature DCs [41,42]. Moreover, we recently demon-
strated an accumulation of immature Langerin+ dendritic
cells in the small airways of patients with COPD, which
was associated with significantly increased expression of
MIP3α/CCL20 in lungs and induced sputum of patients
with COPD compared with "healthy" smokers without
airway obstruction [43]. TGF-β1 has been shown to medi-
ate recruitment of macrophages in COPD [44] and can
also induce the differentiation of peripheral blood mono-
cytes into DCs [45]. The lower levels of both MIP-3α/
CCL20 and TGF-β1 in NK1-R-/- mice can, at least partially,
explain the reduced numbers of DCs and macrophages in
these mice. Importantly, we confirmed the in vivo role of
the NK1 receptor in CS-induced recruitment of macro-
phages and DCs by using the NK1 receptor antagonist RP
67580. Indeed, daily treatment with the antagonist pre-
vented the significant CS-induced increase in macro-
phages and DCs that was seen in control animals.
In steady-state situations, airway macrophages are pre-
dominantly maintained by cell proliferation and to a
lesser extent from monocyte precursor influx [46], while
the rapid turn-over [33] of DCs suggest a continuous
influx of precursors from the circulation. This different
maintenance mechanism may explain why the macro-
phage population in naïve animals is not affected by the
absence of the tachykinin NK1 receptor, while DC popula-
tion is decreased. The precise mechanism responsible for
this steady state influx is not known although age and
environmental air quality seem to be involved. In the
scope of this observation it is important to notice that DC
levels from 'old' NK1-R-/- mice did no longer differ from
WT mice.
Despite the evidence for a chemotactic effect of substance
P on neutrophils [36], no differences in neutrophil influx
between NK1 receptor WT and NK1-R-/- mice were
observed. This correlated with equal amounts of the neu-
trophil attractant KC (the mouse homolog for IL-8) in
both genotypes, but is in contrast with the observations of
Matsumoto and colleagues. They reported that acute ciga-
rette smoke-exposure of guinea pigs induced airway neu-
trophilia, which was inhibited with a dual tachykinin
NK1/NK2 receptor antagonist [22]. However, the effect on
airway neutrophilia in this study may be the result of
blocking the NK2 receptor, which was left unblocked in
the current study. Also, differences in duration of the
smoke protocol and the resulting strenght of the inflam-
Effect of chronic cigarette smoke exposure on the protein lev ls MMP-12 in lung ti sueFigure 5
Effect of chronic cigarette smoke exposure on the 
protein levels of MMP-12 in lung tissue. Semiquantita-
tive scoring of MMP-12 on immunohistochemical stained lung 
tissue sections of wild type and NK1-R-/- mice upon chronic 
(24 weeks) exposure to air or cigarette smoke (A). Photom-
icrograhps of immunohistochemistry for MMP-12 protein on 
lung tissue of wild type and NK1-R-/- mice upon chronic (24 
weeks) exposure to air or cigarette smoke (magnification 
×400). (B) air-exposed wild type mice, (C) cigarette smoke-
exposed wild type mice, (D) air-exposed NK1-R-/- mice and 
(E) cigarette smoke-exposed NK1-R-/- mice. Photomicro-
graphs are representative of 8 animals per group.Page 8 of 12
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Effect of the NK1 receptor antagonist on cigarette smoke-induced inflammation in bronchoalveolar lavage fluidFigure 6
Effect of the NK1 receptor antagonist on cigarette smoke-induced inflammation in bronchoalveolar lavage 
fluid. Total bronchoalveolar lavage (BAL) cells and cell differentiation in BAL fluid of C57BL/6 mice upon IP injection with 
either 0.1 or 1 μg/μl of the NK1 receptor antagonist RP 67580 or diluent and subsequent exposure to air or cigarette smoke 
for 2 weeks: (A) Total BAL cells, (B) macrophages, (C) dendritic cells, (D) neutrophils and (E) lymphocytes. Results are 
expressed as means ± SEM. N = 8 animals per group (* p < 0.05).
Respiratory Research 2009, 10:37 http://respiratory-research.com/content/10/1/37matory response may be of importance, as we did demon-
strate an effect of the NK1 receptor antagonist RP 67580
on the neutrophil accumulation upon short time (2
weeks) CS-exposure.
Lymphocytes also express a functional tachykinin NK1
receptor [47] and are expected to migrate towards sub-
stance P [48]. However, the lack of the tachykinin NK1
receptor did not impair the CS-induced accumulation of
lymphocytes in BAL fluid and lungs in our mouse model,
nor did it affect the formation of peribronchial lymphoid
follicles. These observations are in line with our previous
work, where we demonstrated that the tachykinin NK1
receptor is not required for antigen-induced inflammatory
cell influxes in the airway lumen of mice [49].
Chronic exposure to CS resulted in the development of
pulmonary emphysema in WT mice. However, this
enlargment of alveolar spaces was not observed in NK1-R-
/- mice. Alveolar destruction in pulmonary emphysema is
believed to originate mainly from an imbalance between
proteases and their inhibitors. Macrophages and DCs are
the main sources of MMP-12, a matrix metalloproteinase
that has been described as the key proteolytic enzyme in
the development of CS-induced emphysema in mice [31].
The lower numbers of both macrophages and DCs in CS-
exposed NK1-R-/- mice should thus result in a diminished
release of MMP-12 in these mice. Moreover, immunohis-
tochemical staining showed impaired production of
MMP-12 in alveolar macrophages of CS-exposed NK1-R-/-
mice. This correlates with the findings of Xu and col-
leagues, who described a significant correlation between
substance P and MMP-12 in CS-exposed mice [50,51].
Other mechanisms that can lead to destruction of lung tis-
sue, like alveolar cell apoptosis [52], should also be con-
sidered. Interestingly, Lucatelli and colleagues
demonstrated a role for the NK1 receptor in lung epithelial
cell death [53]. The possible protection against emphy-
sema in the NK1-R-/- mice should nevertheless be regarded
with caution, as the air-exposed NK1-R-/- mice already
have enlarged alveolar spaces and more alveolar destruc-
tion, compared to the WT mice, which makes it difficult to
compare CS-induced emphysema between WT and NK1-
R-/- mice. Baseline differences in lung morphology have
already been described in other strains, such as C3H/HeJ
mice [54].
As a therapeutic approach, blocking only the NK1 receptor
is most likely insufficient, as most of the effects of tachy-
kinins in the airways are mediated by more than one tach-
ykinin receptor. Indeed, not only the NK1, but also NK2
and NK3 receptors can elicit features like airway smooth
muscle contraction, vascular engorgement, mucus secre-
tion, cholinergic nerve activation and recruitment of
inflammatory cells [55,56]. Triple NK receptor antago-
nists have already been successful in reducing bronchoc-
onstriction in patients with asthma [57], and could thus
be ideal candidates for therapeutic intervention in COPD
patients.
To conclude, the tachykinin NK1 receptor is involved in
the accumulation of inflammatory cells in the airways
during the inflammatory response to CS in a mouse
model of COPD. As inflammation of the airways is an
important characteristic of COPD, these findings may
have implications in the future treatment of this devastat-
ing disease. Lower numbers of macrophages and DCs,
combined with impaired release of MMP-12, also resulted
in an attenuation of CS-induced pulmonary emphysema
in NK1-R-/- mice. However, further research is needed to
unravel the precise mechanism by which signalling
through the tachykinin NK1 receptor causes the increased
accumulation of macrophages and DCs into the airway
lumen upon cigarette smoke exposure and to clearly dem-
onstrate a possible beneficial effect of tachykinin receptor
antagonists in people suffering from COPD.
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